Top Peptides for Muscle Growth & Recovery 2026
CJC-1295/Ipamorelin, IGF-1 LR3, BPC-157, and TB-500 — mechanisms, clinical data, and four research stacks from basic recovery to comprehensive anabolic optimization.
How Peptides Support Muscle Growth
Peptides relevant to the muscle growth and recovery research literature fall into three broad mechanistic categories. Growth hormone secretagogues (e.g. CJC-1295, Ipamorelin) act on the pituitary to stimulate endogenous GH release. IGF-1 analogs (e.g. IGF-1 LR3) directly engage IGF-1 receptor signaling — the IGF-1/PI3K/Akt/mTOR pathway is the most extensively studied driver of muscle protein synthesis and is also a key regulator of muscle atrophy [4][5]. Recovery peptides (BPC-157, TB-500) are studied primarily in animal injury models for tissue repair, not for direct muscle growth. The summary below describes what each compound does in the published literature — not what it "does" in humans seeking muscle growth, since direct human efficacy evidence for that endpoint is essentially nonexistent across this group.
CJC-1295 and Ipamorelin
CJC-1295 (CAS 863288-34-0) is a long-acting GHRH analog. In a randomized, placebo-controlled human ascending-dose study in healthy adults, single subcutaneous CJC-1295 doses produced dose-dependent GH increases of approximately 2–10× and IGF-1 elevations of 1.5–3× over baseline, with an estimated half-life of ~5.8–8.1 days[1]. That paper also reported tolerability with no serious adverse reactions — but it is a small, short, healthy-volunteer endocrinology study, not a muscle-growth efficacy trial.
Ipamorelin (CAS 170851-70-4) is a selective growth hormone secretagogue receptor (GHS-R1a) agonist — characterized in the foundational Raun et al. 1998 study as releasing GH without significant effects on ACTH or cortisol in animal models, even at doses well above the GH-releasing ED50[2]. The pairing of a GHRH analog with a GHS-R1a agonist is widely used in research as a way to engage two complementary pituitary GH-release pathways. Whether this translates to durable changes in muscle mass in healthy humans has not been established.
CJC-1295/Ipamorelin — $45.00IGF-1 LR3 (Long-Arg3 IGF-I)
IGF-1 LR3 (CAS 946870-92-4) is a modified IGF-1 with an N-terminal extension and an Arg-3 substitution. Both modifications reduce its affinity for IGF-binding proteins (IGFBPs), which normally sequester native IGF-1 in circulation. In Tomas et al.'s rat work, the LR3 analog was less tightly bound by IGFBPs and was cleared more rapidly in vivo, with greater bioactivity per injected dose than native IGF-I in growth-promoting endpoints[3]. Specific human pharmacokinetic numbers (often quoted as "20–30 hour half-life" in non-peer-reviewed sources) are not well-supported in the human peer-reviewed literature.
The downstream signaling axis IGF-1 engages — IGF-1R → IRS-1 → PI3K → Akt → mTORC1 (p70S6K, 4E-BP1) — is one of the most extensively characterized regulators of skeletal muscle protein synthesis and hypertrophy in animal and cell-culture work, and the same axis suppresses FoxO-mediated atrophy programs [4][5]. Whether systemic IGF-1 LR3 administration produces clinically meaningful muscle hypertrophy in healthy humans is not established by controlled trials.
IGF-1 LR3 1mg — $71.99View Pre-Built Recovery & Growth Stacks
Wolverine Stack, GH optimization, and comprehensive anabolic combinations — pre-selected at every price point.
View All StacksThe Wolverine Stack: BPC-157 + TB-500
In animal injury models, BPC-157 and Thymosin Beta-4 (TB-500) act through largely non-overlapping mechanisms — BPC-157 via vascular/angiogenic signaling, Tβ4 via actin dynamics and cell migration. Direct human muscle-growth or recovery trials of either compound are not available.
For a deeper head-to-head, see our companion article: BPC-157 vs TB-500: Preclinical Evidence Comparison.
- → Pro-angiogenic activity associated with VEGFR2 / Akt / eNOS signaling in animal and CAM assays [7]
- → Promotes tendon fibroblast migration and outgrowth in vitro [11]
- → Reported acceleration of histological tendon healing in rat Achilles transection models [6]
- → Most published animal data come from a single research group; long-term and human safety data are limited
- → Predominant intracellular G-actin sequestering protein in many cell types [10]
- → Activates integrin-linked kinase (ILK) and Akt signaling — characterized in mouse cardiac repair model [8]
- → Promotes hair follicle stem cell migration and dermal repair in rodents [9]
- → Human pharmacokinetic data limited; specific half-life numbers in non-peer-reviewed sources should be treated cautiously
Sample Research Stacks
Combinations below describe how researchers typically pair these compounds based on the mechanisms above. They are not human dosing recommendations or efficacy claims.
- CJC-1295/Ipamorelin — $45.00
- Bacteriostatic Water (x2) — $19.98
Dual-receptor GH secretagogue. Evening administration aligns with natural GH circadian peak during slow-wave sleep.
- BPC-157 10mg — $53.99
- TB-500 10mg — $53.99
- Bacteriostatic Water (x2) — $19.98
Complementary angiogenesis and actin dynamics mechanisms. Covers the full tissue repair cascade.
- CJC-1295/Ipamorelin — $45.00
- IGF-1 LR3 1mg — $71.99
- BPC-157 10mg — $53.99
GH axis optimization + direct IGF-1R signaling + localized recovery. Three-pathway approach.
- BPC-157 10mg — $53.99
- TB-500 10mg — $53.99
- Bacteriostatic Water (x2) — $19.98
For tendon, ligament, and musculoskeletal support structures. BPC-157 documented Achilles repair + TB-500 collagen deposition.
Frequently Asked Questions
Answers describe published findings and known limitations — not human therapeutic guidance.
GH secretagogues (e.g. CJC-1295, Ipamorelin) act on pituitary receptors (GHRH receptor and GHS-R1a, respectively) to stimulate endogenous GH release, broadly preserving feedback regulation. Recombinant GH bypasses the pituitary and supplies hormone directly. The two approaches produce different hormone-profile shapes in published endocrinology studies; comparative efficacy and safety in healthy people pursuing muscle growth has not been established.
IGF-1 LR3 carries an N-terminal extension and an Arg-3 substitution that reduce its affinity for IGFBPs, the binding proteins that sequester native IGF-1 in circulation. In rodent work, this translated to greater bioactivity per injected dose for growth-promoting endpoints (Tomas et al.). Specific human PK numbers commonly quoted online (e.g. "20–30 hour half-life") are not well supported by peer-reviewed human pharmacokinetic data.
Direct human controlled trials for muscle hypertrophy as an endpoint are essentially absent for all five peptides discussed here. CJC-1295 has the strongest human data of the group — but only as a healthy-volunteer endocrinology study showing GH/IGF-1 elevation, not muscle-mass change. BPC-157 and TB-500/Tβ4 evidence is overwhelmingly preclinical (animal and in vitro).
No. None of CJC-1295, Ipamorelin, IGF-1 LR3, BPC-157, or TB-500/Tβ4 is FDA-approved for any human therapeutic indication, including muscle growth or recovery. They are sold as research chemicals for laboratory use.
Animal toxicity reviews for BPC-157 report wide tolerability margins, but most data come from a single research group and human safety studies remain very small. CJC-1295 short-term human tolerability has been reported in healthy adults at modest doses. For Ipamorelin, IGF-1 LR3, and TB-500/Tβ4, human safety data is limited or absent. Long-term effects, drug-drug interactions, and effects in disease states are not well characterized for any of them.
References
Each entry links to PubMed. Animal vs. human evidence is labelled per study so readers can weigh the evidence appropriately. Reading any one study's abstract is encouraged.
- [1]Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PubMed PMID: 16352683 Human (healthy adults, PK/PD)
- [2]Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. PubMed PMID: 9849822 Animal + in vitro
- [3]Tomas FM, Lemmey AB, Read LC, Ballard FJ. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J Endocrinol. 1996;150(1):77–84. PubMed PMID: 8708565 Animal (rat)
- [4]Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol. 2003;5(2):87–90. PubMed PMID: 12563267 Review
- [5]Glass DJ. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr Top Microbiol Immunol. 2010;346:267–278. PubMed PMID: 20593312 Review
- [6]Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–983. PubMed PMID: 14554208 Animal (rat) + in vitro
- [7]Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333. PubMed PMID: 27847966 Animal (CAM, rat hindlimb)
- [8]Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–472. PubMed PMID: 15565145 Animal (mouse cardiac)
- [9]Philp D, Nguyen M, Scheremeta B, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004;18(2):385–387. PubMed PMID: 14657002 Animal (rat, mouse)
- [10]Cassimeris L, Safer D, Nachmias VT, Zigmond SH. Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes. J Cell Biol. 1992;119(5):1261–1270. PubMed PMID: 1447300 In vitro (human PMNs)
- [11]Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. PubMed PMID: 21030672 In vitro (rat tendon fibroblasts)
Limitations to keep in mind: most evidence cited above is from animal models or in vitro work. Direct human controlled trials with muscle hypertrophy as an endpoint are essentially absent for every peptide on this page. CJC-1295 carries the strongest single piece of human data — but only for endocrine endpoints (GH/IGF-1 elevation), not for muscle mass.
Build Your Recovery Stack
Research-grade BPC-157, TB-500, CJC-1295/Ipamorelin, and IGF-1 LR3 from our partner research supplier — for laboratory research use only.